Clinical data | |
---|---|
Other names | LY 300502 |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C14H16ClNO |
Molar mass | 249.74 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Bexlosteride is a potent and noncompetitive inhibitor of the enzyme 5α-reductase related to finasteride and dutasteride. It is selective for the type I isoform of the enzyme. It advanced to Phase III clinical trials, but development was halted at that stage, and it was never marketed.
See also
References
- ^ Chang C (2002). Androgens and androgen receptor : mechanisms, functions, and clinical application. Boston: Kluwer Academic Publishers. ISBN 1-4020-7188-4.
- Lednicer D (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 978-0-470-19039-5.
- "Drug Profile: Bexlosteride". Adis Insight.
- Reaxys entry for bexlosteride: Reaxys Registry Number: 6635310
Drugs used in benign prostatic hyperplasia (G04C) | |
---|---|
5α-Reductase inhibitors | |
Alpha-1 blockers | |
Steroidal antiandrogens | |
Herbal products | |
Others |